Mabylon

Raised $18.5M, announced 12 August 2025.

Total raised: $18.5M

Country SwitzerlandSector Health

Round

$18.5MRound, 12 August 2025

Funds advance peanut allergy candidate MY006 toward clinical proof of concept.

Amount: $18.5M
Announced: 12 August 2025
Lead: Existing private investors, mainly former Roche management and board members
Use of funds: Funds advance peanut allergy candidate MY006 toward clinical proof of concept.
Checked: Announced by the company
Sources: Swiss biotech Mabylon lands €32M to fight peanut allergies (tech.eu EUR-normalized, likely CHF) swissbiotech.org
Swiss biotech Mabylon lands €32M to fight peanut allergies (tech.eu EUR-normalized, likely CHF) siliconcanals.com

Company

Develops human-derived antibody drugs for allergies, neurodegeneration and inflammation

Based in: Zurich, Switzerland
Sector: Health
Website: mabylon.com ↗

Questions

How much has Mabylon raised?

Mabylon raised $18.5M, announced on 12 August 2025.

Who invested in Mabylon?

Existing private investors, mainly former Roche management and board members led. Investors include Existing private investors, mainly former Roche management and board members.